Argistad 1G

Rx

Indications:

• Maintenance treatment for hyperammonemia in patients with deficiency of carbamoylphosphate synthetase, ornithine transcarbamylase.
• Maintenance treatment in patients with hyperammonemia, citrullinemia, argininosuccinic aciduria.
• Support treatment of dyspepsia.
• Support treatment to improve the exercising ability in patients with stable cardiovascular disease.
• Nutritional supplementation for patients with urea cycle disorders such as: Hyperammonemia type I and II, citrullinemia, argininosuccinic aciduria and with deficiency of the enzymes N-acetylglutamate synthase.

Dosage:

• Maintenance treatment for hyperammonemia in patients with deficiency of carbamoylphosphate synthetase, ornithine transcarbamylase: Newborns and infants aged from 1 – 18 months: 0.5 ml/kg/day, divided into 3 – 4 times/day.
• Maintenance treatment in patients with hyperammonemia, citrullinemia, argininosuccinic aciduria: Newborns and infants aged from 1 – 18 months: 0.5-0.875 ml/kg/once, taken 3 – 4 times/day with food.
• Support treatment of dyspepsia: Adults: 15-30 ml/day.
• Support treatment to improve the exercising ability in patients with stable cardiovascular disease: Adults: 30 – 105 ml/day, each dose should not exceed 40 ml.
• Nutritional supplementation for patients with urea cycle disorder such as: Hyperammonemia type I and II, citrullinemia, argininosuccinic aciduria and with deficiency of the enzymes N-acetylglutamate synthase: Adults: 15 – 100 ml/day, depend on disease condition.

Usage:

Argistad 1G is administered orally.

• Patients with known hypersensitivity to any ingredients in the formulation.
• Patients with allergic tendencies.
• Patients with urea cycle disorder who have arginase deficiency.

• Abdominal pain and bloating, decreased platelet count and exacerbation of acrocyanosis, exacerbation of sickle cell anemia, and elevations of BUN and serum creatine and creatinine.
• Allergic reaction, characterized by macular rash with redness and swelling of the hands and face, that subsided rapidly following discontinuance of the drug and administration of diphenhydramine.

• Precaution of sugar content (2 g per 5 ml) when prescribing for diabetic and low-sugar diet patients.
• If diarrhoea occurs, should discontinue the drug. Arginine should be used cautiously in patients with renal disease or anuria.
• When used for acute hyperammonaemia, administration of high arginine dosages may cause hyperchloremic metabolic acidosis; therefore, plasma chloride and bicarbonate concentrations should be monitored and simultaneous administration of appropriate amounts of bicarbonate may be required.
• Arginine is ineffective for treatment of hyperammonaemia caused by organic acidemias.
• This drug should not be used during pregnancy. Caution should be exercised when arginine is administered to nursing women.